Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics

Nature Medicine

Volumn 7, Issue 1, 2001, Pages 33-40

  Kay, Mark A ^a   Glorioso, Joseph C ^b   Naldini, Luigi ^c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIS ACTING ELEMENT; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANTIGEN PRESENTING CELL; GENE SEQUENCE; GENE THERAPY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMORAL IMMUNITY; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT GENE; RETROVIRUS; REVIEW; VIRION; VIRUS CONCENTRATION; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS RECOMBINANT;

GENE THERAPY; GENETIC VECTORS; VIRUSES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; DNA VIRUSES; HERPES; LENTIVIRUS; RNA VIRUSES; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0035135747     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/83324     Document Type: Review

References (127)

1. Prodrug activation enzymes in cancer gene therapy
2. Cytokine gene transfer in cancer therapy
3. Progress in antiangiogenic gene therapy of cancer
4. Gene therapy for cancer: What have we done and where are we going?
5. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
6. Replication-selective adenoviruses as oncolytic agents
7. Regulated gene expression systems
8. Human gene marker/therapy clinical protocols
9. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences
10. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs and endogenous retroviral sequences
11. No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus
12. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis
13. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cell
14. Integration of murine leukemia virus DNA depends on mitosis
15. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
16. Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest
17. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
18. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
19. Excellent tools for experimental gene transfer and promising candidates for gene therapy
20. HIV-1 nuclear import: In search of a leader
21. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
22. A third-generation lentivirus vector with a conditional packaging system
23. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
24. Development of a self-inactivating lentivirus vector
25. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells
26. Gene transfer vectors derived from equine infectious anemia virus
27. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors
28. Stable gene transfer to the nervous system using a non-primate lentiviral vector
29. Efficient transfer, integration and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
30. Lentiviral gene transfer to the nonhuman primate brain
31. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer
32. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer
33. Parkinson's disease: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
34. Correction of neuropathology and protection against learning impairments in affected mice
35. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo
36. Efficient lentiviral transduction of liver requires cell cycling in vivo
37. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver
38. Sustained expression of genes delivered directly into the liver and muscle by lentiviral vectors
39. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors
40. Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells
41. -bone marrow and cord blood-derived SCID-repopulation cells with third-generation lentiviral vectors
42. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human betaglobin
43. Helper-free foamy virus vectors
44. Adenovirus vectors for gene delivery
45. Adenovirus-mediated in vivo gene transfer
46. Adenoviral vectors for gene transfer
47. Human adenovirus vectors for gene transfer into mammalian cells
48. Adenoviruses
49. Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle
50. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
51. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
52. Strategies to adapt adenoviral vectors for targeted delivery
53. Targeting adenovirus
54. Adenovirade: The viruses and their replication
55. Region E3 of adenovirus: A cassette of genes involved in host immunosurveillance and virus-cell interactions
56. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression
57. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains
58. Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice
59. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4lg administration
60. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
61. + CTLs in vivo
62. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
63. E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors
64. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3
65. Modulation of the inflammatory properties and hepatoxicity of recombinant adenovirus vectors by the viral E4 gene products
66. Toxicology comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery
67. Expanded-capacity adenoviral vectors - The helper-dependent vectors
68. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
69. High doses of a helper dependent adenoviral vector yield supraphysiologica levels of alpha 1-antitrypsin with negligible toxicity
70. Method for multiple portal vein infusions in mice: Quantitation of adenovirus-mediated hepatic gene transfer
71. The use of adenoviral vectors for gene therapy and gene transfer in vivo
72. Gene therapy for cystic fibrosis
73. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
74. Use of adeno-associated virus as a general transduction vector for mammalian cells
75. Adeno-associated virus vectors and hematology
76. Adeno-associated virus vectors for gene therapy: More pros than cons?
77. Adeno-associated virus-based vectors in gene therapy
78. Adeno-associated virus vectors can be efficiently produced without helper virus
79. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
80. Production and purification of recombinant adeno-associated virus
81. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses
82. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue
83. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver
84. The kinetics of rAAV integration in the liver
85. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle
86. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo
87. Structural analysis of adeno-associated virus transduction circular intermediates
88. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination
89. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors
90. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
91. From the cover: Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
92. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
93. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors
94. AAV vectors: Is clinical success on the horizon?
95. Nonrandom transduction of recombinant adeno-associated viral vectors in mouse hepatocytes in vivo: Cell cycling does not influence hepatocyte transduction
96. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: α-, β-, γ-, or δ- sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors
97. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus
98. Evidence for gene transfer and expression of blood coagulation factor IX in patients with severe hemophilia B treated with an AAV vector
99. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications
100. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins
101. Systemic delivery of nerve growth factor following herpesvirus gene transfer
102. The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning amplifying vector
103. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: Rescue of replication-competent virus progeny and packaging of amplicon vectors
104. Herpes simplex virus vector-based gene therapy for malignant glioma
105. Effect of a modified herpes simplex virus expressing nerve growth factor on taxol-induced neuropathy in mice
106. Nerve growth factor (NGF) gene therapy improves rat diabetic cystopathy, but does not increase pain sensation
107. Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy
108. HSV vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine induced degeneration of neurons in the substantia nigra in vivo
109. Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors
110. Significantly increased expression of β-glucuronidase in the central nervous system of mucopolysaccharidosis type VII mice from the latency-associated transcript promoter in a nonpathogenic herpes simplex virus type 1 vector
111. Antinociceptive effect of gene transfer with HSV vector coding for human preproenkephalin
112. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglia neurons from peroxide toxicity
113. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes
114. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector
115. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region
116. Site-specific integration by adeno-associated virus
117. Genomic integration and gene expression by a modified adenoviral vector
118. A phage integrase directs efficient site-specific integration in human cells
119. Mammalian genomes contain active recombinase recognition sites
120. Gene therapy using SV-40 derived vectors: What does the future hold
121. RNA viruses: Emerging vectors for vaccination and gene therapy
122. Evaluation of recombinant alphaviruses as vectors in gene therapy
123. Development of replicative and nonreplicative hepatitis B virus vectors
124. Negative-strand RNA viruses: Genetic engineering and applications
125. Epstein-Barr virus vectors for gene expression and transfer